Atux Iskay

Atux Iskay is a biotechnology company based in Cambridge, Massachusetts, focused on the discovery and development of novel small molecule therapeutics. The company specializes in targeting challenging protein-protein interactions (PPIs) that have historically been considered undruggable. Backed by Atlas Venture, Atux Iskay utilizes a proprietary platform that integrates structural biology and advanced medicinal chemistry to design high-affinity inhibitors. Their current pipeline is focused on high-value targets within the fields of oncology and immunology. The company aims to translate deep mechanistic insights into transformative medicines for patients with significant unmet medical needs.